HT 6289
Alternative Names: HT-6289Latest Information Update: 28 Aug 2023
At a glance
- Originator Halia Therapeutics
- Class Small molecules
- Mechanism of Action NEK7 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastrointestinal disorders
Most Recent Events
- 20 Jul 2023 Preclinical trials in Gastrointestinal disorders in USA (unspecified route), before July 2023 (Halia Therapeutics pipeline, July 2023)
- 20 Jul 2023 Halia Therapeutics plans to file IND application to the regulatory authority by Q1 2024 (Halia Therapeutics pipeline, July 2023)